Retinoic acid syndrome: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
==Background==
==Background==
*Differentiation syndrome (DS) is most current term
*APML pts undergoing ATRA treatment (Tretinoin, Vesanoid)
**And/or with arsenic trioxide therapy (Trisenox, ATO)
**ATRA differentiates APML blasts into mature granulocytes
**Differentiation of blasts may cause "cytokine storm" and lead to tissue damage
*Incidence of DS<ref>Montesinos P and Sanz MA. The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011059.</ref>
**Up to 25% of pts undergoing ATRA Tx
**Up to 31% of pts undergoing ATO Tx
*Up to 40% mortality in patients requiring mechanical ventilation
*Diagnosis made clinically with symptomology and includes immediate treatment with steroids
**Steroid treatment highly recommended even if other ddx possible


==Differential==
*[[Sepsis]]
*Fungal infection
*Pulmonary hemorrhage
*[[Pneumonia]]
*Renal failure
*[[CHF]]
*[[Pulmonary embolism]]
*[[DIC]]
==Clinical Features==
*Unexplained fever
*Unexplained hypotension
*Weight gain > 5 kg
*Dyspnea with pulmonary infiltrates
*[[Pericardial effusion]]
*Pleural effusion
*Renal failure
*Vascular capillary leak syndrome
*[[DIC]]
*Never observed beyond induction therapy, when pt has achieved complete response
==Diagnostics==
*Troponins for pericarditis
*Severe leukocytosis on CBC
*[[Sepsis]] workup
*[[CHF]] workup, echo
*[[Pulmonary embolism]] workup
*[[DIC]] workup
*Diagnostic bronchoscopy, BAL, bx usually not required
*Imaging
**CXR - pleural effusions, ground-glass opacities, increased cardiac silhouette
**CT chest - pleural effusions, peripheral nodules
==Management<ref>Sanz MA and Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. May 1, 2014; Blood: 123 (18).</ref>==
*Dexamethasone 10 mg IV q12hrs
**Continue treatment until complete disappearance of signs and symptoms
*Temporary d/c ATRA or ATO only in severe cases of DS (renal failure or ICU admit)
*Furosemide for fluid overload
*CRRT for refractory renal failure
*Supportive
**Mechanical ventilation for respiratory failure
**Careful IVF admin, prioritizing blood products for coagulopathies (DIC)
**Vasopressors
**Empiric antibiotics
**Avoid invasive pleural/pericardial effusion diagnostics


==Sources==
==Sources==
*Weerakkody Y et al. All trans retinoic acid syndrome. Radiopaedia. http://radiopaedia.org/articles/all-trans-retinoic-acid-syndrome.


==Sources==
<references/>
<references/>


[[Category:Heme/Onc]]
[[Category:Heme/Onc]]

Revision as of 22:58, 2 May 2016

Background

  • Differentiation syndrome (DS) is most current term
  • APML pts undergoing ATRA treatment (Tretinoin, Vesanoid)
    • And/or with arsenic trioxide therapy (Trisenox, ATO)
    • ATRA differentiates APML blasts into mature granulocytes
    • Differentiation of blasts may cause "cytokine storm" and lead to tissue damage
  • Incidence of DS[1]
    • Up to 25% of pts undergoing ATRA Tx
    • Up to 31% of pts undergoing ATO Tx
  • Up to 40% mortality in patients requiring mechanical ventilation
  • Diagnosis made clinically with symptomology and includes immediate treatment with steroids
    • Steroid treatment highly recommended even if other ddx possible

Differential

Clinical Features

  • Unexplained fever
  • Unexplained hypotension
  • Weight gain > 5 kg
  • Dyspnea with pulmonary infiltrates
  • Pericardial effusion
  • Pleural effusion
  • Renal failure
  • Vascular capillary leak syndrome
  • DIC
  • Never observed beyond induction therapy, when pt has achieved complete response

Diagnostics

  • Troponins for pericarditis
  • Severe leukocytosis on CBC
  • Sepsis workup
  • CHF workup, echo
  • Pulmonary embolism workup
  • DIC workup
  • Diagnostic bronchoscopy, BAL, bx usually not required
  • Imaging
    • CXR - pleural effusions, ground-glass opacities, increased cardiac silhouette
    • CT chest - pleural effusions, peripheral nodules

Management[2]

  • Dexamethasone 10 mg IV q12hrs
    • Continue treatment until complete disappearance of signs and symptoms
  • Temporary d/c ATRA or ATO only in severe cases of DS (renal failure or ICU admit)
  • Furosemide for fluid overload
  • CRRT for refractory renal failure
  • Supportive
    • Mechanical ventilation for respiratory failure
    • Careful IVF admin, prioritizing blood products for coagulopathies (DIC)
    • Vasopressors
    • Empiric antibiotics
    • Avoid invasive pleural/pericardial effusion diagnostics

Sources

  1. Montesinos P and Sanz MA. The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011059.
  2. Sanz MA and Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. May 1, 2014; Blood: 123 (18).